Actively Recruiting
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
Led by University of Alabama at Birmingham · Updated on 2026-05-07
200
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel intervention and improve treatment outcomes.
CONDITIONS
Official Title
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years and older
- Currently prescribed methadone, extended-release naltrexone (XR-NTX), or buprenorphine for opioid use disorder, or healthy control participants
- Stable on medication for opioid use disorder with no dose changes for the past month
- Positive urine drug screen for buprenorphine or methadone if prescribed those medications
You will not qualify if you...
- Any history or exam evidence of eye diseases such as cataracts, retinopathy, glaucoma, amblyopia, scotoma, color or night blindness, corneal problems, macular degeneration, or retinitis pigmentosa
- Acutely suicidal, manic, intoxicated, or unstable to provide informed consent
- Self-reported use of illicit opioids, stimulants, benzodiazepines, sedatives, or hypnotics in the past month
- Severe alcohol or cannabis use disorder according to DSM-5 checklist
- Positive urine drug screen for illicit opioids, stimulants, benzodiazepines, sedatives, or hypnotics
- Shift workers with work hours outside 7 a.m. to 6 p.m.
- Diagnosis of narcolepsy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
Research Team
K
Karen Cropsey, PsyD
CONTACT
B
Brionna Smith, B.S.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here